A detailed history of Telemus Capital, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Telemus Capital, LLC holds 25,110 shares of BMY stock, worth $1.47 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
25,110
Previous 25,657 2.13%
Holding current value
$1.47 Million
Previous $1.49 Million 13.5%
% of portfolio
0.11%
Previous 0.14%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 01, 2024

SELL
$48.48 - $57.85 $26,518 - $31,643
-547 Reduced 2.13%
25,110 $1.29 Million
Q3 2023

Oct 25, 2023

SELL
$57.89 - $64.73 $83,824 - $93,729
-1,448 Reduced 5.34%
25,657 $1.49 Million
Q2 2023

Jul 10, 2023

BUY
$63.71 - $70.74 $57,912 - $64,302
909 Added 3.47%
27,105 $1.73 Million
Q1 2023

Apr 11, 2023

BUY
$65.71 - $74.53 $54,539 - $61,859
830 Added 3.27%
26,196 $1.82 Million
Q4 2022

Jan 11, 2023

SELL
$68.48 - $81.09 $32,801 - $38,842
-479 Reduced 1.85%
25,366 $0
Q3 2022

Oct 11, 2022

BUY
$0.13 - $76.84 $44 - $26,279
342 Added 1.34%
25,845 $1.84 Million
Q2 2022

Aug 10, 2022

SELL
$72.62 - $79.98 $170,439 - $187,713
-2,347 Reduced 8.43%
25,503 $1.96 Million
Q1 2022

Apr 06, 2022

BUY
$61.48 - $73.72 $7,377 - $8,846
120 Added 0.43%
27,850 $2.03 Million
Q4 2021

Feb 01, 2022

SELL
$53.63 - $62.52 $29,979 - $34,948
-559 Reduced 1.98%
27,730 $1.73 Million
Q3 2021

Oct 27, 2021

SELL
$59.17 - $69.31 $448,863 - $525,785
-7,586 Reduced 21.15%
28,289 $1.67 Million
Q2 2021

Aug 09, 2021

SELL
$61.91 - $67.42 $114,285 - $124,457
-1,846 Reduced 4.89%
35,875 $2.4 Million
Q1 2021

Apr 20, 2021

BUY
$59.34 - $66.74 $458,223 - $515,366
7,722 Added 25.74%
37,721 $2.38 Million
Q4 2020

Jan 28, 2021

BUY
$57.74 - $65.43 $111,957 - $126,868
1,939 Added 6.91%
29,999 $1.86 Million
Q3 2020

Nov 02, 2020

BUY
$57.43 - $63.64 $366,862 - $406,532
6,388 Added 29.48%
28,060 $1.72 Million
Q2 2020

Jul 17, 2020

SELL
$54.82 - $64.09 $4,111 - $4,806
-75 Reduced 0.34%
21,672 $1.25 Million
Q1 2020

Jun 05, 2020

SELL
$46.4 - $67.43 $346,700 - $503,836
-7,472 Reduced 25.57%
21,747 $1.3 Million
Q4 2019

Jan 24, 2020

BUY
$49.21 - $64.19 $417,497 - $544,587
8,484 Added 40.92%
29,219 $1.88 Million
Q3 2019

Nov 12, 2019

BUY
$42.77 - $50.71 $12,831 - $15,213
300 Added 1.47%
20,735 $1.05 Million
Q2 2019

Aug 09, 2019

SELL
$44.62 - $49.34 $47,564 - $52,596
-1,066 Reduced 4.96%
20,435 $927,000
Q1 2019

May 02, 2019

SELL
$45.12 - $53.8 $22,875 - $27,276
-507 Reduced 2.3%
21,501 $1.03 Million
Q4 2018

Feb 06, 2019

SELL
$48.76 - $63.23 $80,454 - $104,329
-1,650 Reduced 6.97%
22,008 $1.14 Million
Q3 2018

Oct 23, 2018

SELL
$55.19 - $62.25 $21,855 - $24,651
-396 Reduced 1.65%
23,658 $1.47 Million
Q2 2018

Jul 31, 2018

BUY
$50.53 - $62.98 $7,023 - $8,754
139 Added 0.58%
24,054 $1.33 Million
Q1 2018

Apr 27, 2018

SELL
$59.92 - $68.98 $15,279 - $17,589
-255 Reduced 1.06%
23,915 $1.51 Million
Q4 2017

Feb 02, 2018

BUY
$59.94 - $65.35 $1.15 Million - $1.25 Million
19,129 Added 379.47%
24,170 $1.48 Million
Q3 2017

Nov 03, 2017

SELL
$55.23 - $63.74 $413,617 - $477,348
-7,489 Reduced 59.77%
5,041 $321,000
Q2 2017

Apr 03, 2018

BUY
N/A
1,155 Added 10.15%
12,530 $698,000
Q1 2017

Apr 03, 2018

BUY
N/A
11,375
11,375 $619,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Telemus Capital, LLC Portfolio

Follow Telemus Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Telemus Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Telemus Capital, LLC with notifications on news.